PharmaLytica 2021 Hyderabad review.

abc

abc

Panacea and Bharat Biotech in talks for Covaxin production

Bharat biotech looks at contract manufacturing to expand its capacity amidst growing demand for Covid-19 jabs.

09 April, 2021 Mumbai;Panacea Biotec seems to be interested in producing the Covaxin vaccine. As per sources, Panacea hopes to enter into an agreement with Bharat Biotech to produce Covaxin at the company's unit in Delhi.

COVAXIN, India's indigenous COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).

The Hyderabad based company looks at contract manufacturing options to expand its capacity amidst growing demand for Covid-19 jabs. Discussions are at early stage.

It also seems that the two companies want the government to provide funding to increase production capacity. Panacea is said to be ready to produce covaxin in two to three months if it receives funding from the government. Panacea has the Biosafety Level 3 manufacturing unit which is needed to make the coronavirus vaccine.

abc

abc

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More